drug
opicapone
Marketedupdated 5mo agoby $AMRX Amneal Pharmaceuticals, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for parkinson disease.
indications
investigational
Parkinson's Disease
all catalysts(3)
Trials studying opicapone
- —REal-life ON PARKinson's - ITaly (REONPARK-IT)
- phase4OpiCapone Effect on Motor Fluctuations and pAiN
- phase4OpicApone Sleep dISorder
- phase4eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
- phase3Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
- phase4A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 12, 2027
224 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Dec 12, 2032compositionUS 9630955
- Dec 12, 2032compositionUS 9630955
- Jan 11, 2032method-of-use (U-4038)US 12129247
- Jan 11, 2032method-of-use (U-4038)US 12129247
- Mar 31, 2030formulationUS 100710853.5y
- Mar 31, 2030formulationUS 100710853.5y
- Mar 31, 2030method-of-use (U-3869)US 105831303.5y
- Mar 31, 2030method-of-use (U-3869)US 105831303.5y
- Jul 14, 2029method-of-use (U-3869)US 85247462.8y
- Jul 14, 2029method-of-use (U-3869)US 85247462.8y
- Apr 2, 2029compositionUS 81687932.5y
- Apr 2, 2029compositionUS 81687932.5y
- Oct 10, 2027formulationUS 97452901.0y
- Oct 10, 2027formulationUS 97452901.0y
- May 12, 2027compositionUS 8907099224d
- May 12, 2027compositionUS 8907099224d
- Jul 26, 2026method-of-use (U-3872)US 9550759
- Jul 26, 2026method-of-use (U-3872)US 9550759
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that